Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
- 7 September 1999
- journal article
- clinical trial
- Published by Elsevier in Neuroscience Letters
- Vol. 273 (1) , 5-8
- https://doi.org/10.1016/s0304-3940(99)00617-5
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer DiseaseArchives of Neurology, 1999
- Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSFNeurology, 1999
- Prevalence and Incidence of Clinically Diagnosed Memory Impairments in a Geographically Defined General Population in SwedenNeuroepidemiology, 1999
- High Cerebrospinal Fluid Tau and Low Amyloid β42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E GenotypeArchives of Neurology, 1998
- Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up studyJournal of Neurology, Neurosurgery & Psychiatry, 1998
- Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's diseaseNeurology, 1997
- tau protein in cerebrospinal fluidMolecular and Chemical Neuropathology, 1995
- Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)Neuron, 1994
- A4 amyloid protein deposition and the diagnosis of Alzheimer's diseaseNeurology, 1988
- “Mini-mental state”Journal of Psychiatric Research, 1975